Pacdev (enfortumab vedotin), in combination with PD-1 inhibitor Keytruda (pembrolizumab), reached the main goals in a late-stage trial for certain patients with bladder cancer.
Look at where our understanding of cancer was two, five, 10, 15, 20, or more years ago and then consider what has happened over the past two decades. We finally realized how more complex the problem of cancer is—more than any of us imagined.
